0001123292-23-000122.txt : 20231010 0001123292-23-000122.hdr.sgml : 20231010 20231010074048 ACCESSION NUMBER: 0001123292-23-000122 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20231010 DATE AS OF CHANGE: 20231010 EFFECTIVENESS DATE: 20231010 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acasti Pharma Inc. CENTRAL INDEX KEY: 0001444192 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-494122 FILM NUMBER: 231315663 BUSINESS ADDRESS: STREET 1: 3009, BOUL. DE LA CONCORDE EAST STREET 2: SUITE 102 CITY: LAVAL STATE: A8 ZIP: H7E 2B5 BUSINESS PHONE: 450-686-4555 MAIL ADDRESS: STREET 1: 3009, BOUL. DE LA CONCORDE EAST STREET 2: SUITE 102 CITY: LAVAL STATE: A8 ZIP: H7E 2B5 D 1 primary_doc.xml X0708 D LIVE 0001444192 Acasti Pharma Inc. 2572 boul. Daniel-Johnson 2nd Floor Laval A8 QUEBEC, CANADA H7T 2R3 450-686-4555 QUEBEC, CANADA None None Corporation true Prashant Kohli 2572 boul. Daniel-Johnson 2nd Floor Laval A8 QUEBEC, CANADA H7T 2R3 Executive Officer Vimal Kavuru 2572 boul. Daniel-Johnson 2nd Floor Laval A8 QUEBEC, CANADA H7T 2R3 Director Michael Derby 2572 boul. Daniel-Johnson 2nd Floor Laval A8 QUEBEC, CANADA H7T 2R3 Director Donald Olds 2572 boul. Daniel-Johnson 2nd Floor Laval A8 QUEBEC, CANADA H7T 2R3 Director Brian Ford 2572 boul. Daniel-Johnson 2nd Floor Laval A8 QUEBEC, CANADA H7T 2R3 Executive Officer Interim Chief Financial Officer Dr. R. Loch Macdonald 2572 boul. Daniel-Johnson 2nd Floor Laval A8 QUEBEC, CANADA H7T 2R3 Executive Officer Chief Medical Officer Carrie D'Andrea 2572 boul. Daniel-Johnson 2nd Floor Laval A8 QUEBEC, CANADA H7T 2R3 Executive Officer Clinical Operations Amresh Kumar 2572 boul. Daniel-Johnson 2nd Floor Laval A8 QUEBEC, CANADA H7T 2R3 Executive Officer VP of Product Management Biotechnology No Revenues 06b false 2023-09-25 false true true true false 0 15116786 7499793 7616993 The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors under Rule 506(b). false 4 0 0 0 Acasti Pharma Inc. /s/ Prashant Kohli Prashant Kohli CEO 2023-10-10